Aclarion Provides Corporate Update on Nociscan AI Technology Milestones

​​Successful milestones achieved and upcoming include peer-reviewed publications, commercial agreements, and payer coverage decisionsProgressing with proven path toward standard of care addressing chronic low back pain, the largest expenditure in US healthcare costing Americans an estimated $134 Billion annuallyMore than $50 Million has been invested in the promising Aclarion AI platform that aids physicians in identification of painful discsTechnology protected by 23 issued US patents, 17 issued international patents, and 12 pending patent applicationsThree of four largest private insurance payers in the UK now covering NociscanPartnership with ten prominent KOL surgeons signed on to assist Aclarion in successfully gaining traction and reimbursement throughout the United StatesBROOMFIELD, CO – (NewMediaWire) – September 12, 2024 – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today provided a corporate update. The update reviews the successful achievement of several recent key milestones and provides perspective on the positive implications of those catalysts as the Company continues to establish Nociscan as a standard of care decision support tool for the treatment of patients with chronic low back pain.  “We are excited with the recent positive success we have been awarded as Aclarion has consistently achieved stated catalysts of value creation that fall into a very concise framework proven to bring disruptive technological advancements to standard of care in the healthcare sector,” said Brent Ness, CEO of Aclarion. “We intend to lead a positive diagnostic transformation in spine care through clinical and economic evidence that proves the promising value of Nociscan. The building blocks we have executed over the past two years have recently led to the achievement of our most important catalyst to date which is multiple private insurance companies in the UK electing to pay for Nociscan. Payer coverage is critical to driving Nociscan to standard of care. We are providing this corporate update to share the process involved in achieving this milestone, how that process is being replicated at many sites throughout the U.S., how we are coordinating clinical studies in support of payment, and why increasing payer coverage decisions are critical catalysts for driving the valuation of our company. We are clearly excited not only by our recent successes but even more so for our upcoming near term catalysts.”The cornerstone of Aclarion’s strategy to drive payer coverage is to partner with Key Opinion Leader (KOL) physicians who see the value of Nociscan in their practice and advocate for insurance coverage so the physician can provide better care to more patients. Aclarion now has a panel of 10 of the top spine surgeon leaders in the world aligned and actively speaking on behalf of the efficacy and clinical utility of adding Nociscan to the evaluation of patients who suffer from chronic low back pain. “These KOLs are participating in the collection of clinical data, they are engaging insurance companies and benefits management entities to advocate for coverage decisions and representing Nociscan as an important technology worthy of societal endorsement,” said Ryan Bond, Chief Strategy Officer of Aclarion. “We believe the quality of a company’s KOL network is a direct reflection of the importance and promise of any new technology and our list of KOLs is more like that of a multibillion-dollar industry leader than an emerging technology disruptor.”Aclarion’s KOL advocacy strategy applied to the UK has led to great success and is a model of what the Company expects to see replicated with their KOLs in the United States. Physicians in the UK originally set out to evaluate Nociscan technology across 30 patients to determine if the technology was helpful. After comparing Nociscan to invasive discography across only 20 patients, … 

BlogofInnovation.com